GenMont Biotech Incorporation (TPE:3164)

TPE:3164 Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	74.56	110.51	55.6	133.69	169.95	274.85
Short-Term Investments	243.86	248.13	272.71	267.26	251.78	190.28
Cash & Short-Term Investments	318.42	358.64	328.3	400.94	421.73	465.13
Cash Growth	8.95%	9.24%	-18.12%	-4.93%	-9.33%	-11.65%
Accounts Receivable	42.82	31.6	38.23	50.36	54.01	42.35
Other Receivables	0.9	1.73	1.79	1.4	1.05	4.09
Receivables	43.72	33.33	40.02	51.76	55.06	46.44
Inventory	73.82	77.67	88.12	55.3	37.06	34.79
Prepaid Expenses	3.85	4.92	9.07	13.49	66.94	49.59
Other Current Assets	64.07	67.17	-	-	-	-
Total Current Assets	503.86	541.73	465.51	521.5	580.79	595.94
Property, Plant & Equipment	949.05	1,037	1,060	1,113	1,045	922.68
Long-Term Investments	-	6.09	7.32	26.52	34.68	25.33
Other Intangible Assets	2.03	2.16	2.26	0.24	0.33	0.25
Long-Term Deferred Tax Assets	48.66	42.04	39.7	22.73	12.31	7.76
Other Long-Term Assets	75.45	79.89	78.29	11.59	24.8	60.86
Total Assets	1,579	1,709	1,653	1,696	1,698	1,613
Accounts Payable	6.01	6.3	7.85	14.37	11.39	7.39
Accrued Expenses	-	-	-	-	-	23.98
Short-Term Debt	21.45	20.48	-	-	-	-
Current Portion of Long-Term Debt	6.94	12.24	2.24	-	-	-
Current Portion of Leases	1.95	2.4	2.36	1.06	2.11	2.04
Current Income Taxes Payable	7.95	12.19	18.95	28.44	33.82	16.29
Current Unearned Revenue	20.11	40.05	33.98	25.76	25.33	24.3
Other Current Liabilities	40.03	46.48	81.01	91.16	66.51	20.96
Total Current Liabilities	104.44	140.15	146.39	160.78	139.17	94.96
Long-Term Debt	42.65	49.23	20.11	-	-	-
Long-Term Leases	33.01	34.26	33.6	33.49	30.62	32.29
Long-Term Deferred Tax Liabilities	3.11	3.11	1.59	1.96	1.54	1.39
Other Long-Term Liabilities	2.32	2.32	2.37	2.37	2.32	2.32
Total Liabilities	185.54	229.07	204.06	198.59	173.65	130.95
Common Stock	860.1	865.11	865.11	863.71	863.71	863.41
Additional Paid-In Capital	351.77	353.74	377.1	375.69	375.69	386.54
Retained Earnings	87.85	128.02	89.97	117.5	154.87	90.81
Comprehensive Income & Other	-21.57	4.9	-15.88	-5.58	-17.83	-11.49
Total Common Equity	1,278	1,352	1,316	1,351	1,376	1,329
Minority Interest	115.34	127.9	132.82	145.89	147.95	152.6
Shareholders' Equity	1,394	1,480	1,449	1,497	1,524	1,482
Total Liabilities & Equity	1,579	1,709	1,653	1,696	1,698	1,613
Total Debt	106	118.61	58.31	34.55	32.73	34.33
Net Cash (Debt)	212.41	240.03	270	366.4	389	430.8
Net Cash Growth	22.60%	-11.10%	-26.31%	-5.81%	-9.70%	-12.76%
Net Cash Per Share	2.45	2.77	3.12	4.23	4.48	4.89
Filing Date Shares Outstanding	86.01	86.51	86.51	86.37	86.37	86.34
Total Common Shares Outstanding	86.01	86.51	86.51	86.37	86.37	86.34
Working Capital	399.42	401.59	319.12	360.73	441.62	500.98
Book Value Per Share	14.86	15.63	15.22	15.65	15.94	15.40
Tangible Book Value	1,276	1,350	1,314	1,351	1,376	1,329
Tangible Book Value Per Share	14.84	15.60	15.19	15.64	15.93	15.39
Buildings	888.42	923.19	886.14	877.91	168.74	168.41
Machinery	480.01	489.48	481.71	419.15	234.11	230.98
Construction In Progress	0.02	0.02	0.03	75.24	858.62	720.57

Source: S&P Global Market Intelligence. Standard template. Financial Sources.